Should Reckitt prioritize expanding the Mucinex product line or focus on increasing market share of existing formulations?

Introduction

The trade-off question at hand is whether Reckitt should prioritize expanding the Mucinex product line or focus on increasing market share of existing formulations. This scenario involves balancing potential growth through product diversification against deepening market penetration with current offerings. I'll approach this analysis by examining the current product landscape, market dynamics, and potential impacts on Reckitt's business objectives.

Step 1

Clarifying Questions (3 minutes)

• Based on recent market trends, I'm thinking there might be untapped segments in the cold and flu market. Could you provide insights into our current market share across different demographics and any emerging consumer needs we've identified?

Why it matters: Helps determine if expansion or focus is more aligned with market opportunities. Expected answer: Detailed breakdown of market share and identified gaps. Impact on approach: Would influence whether to prioritize new product development or targeted marketing of existing formulations.

• Considering our revenue model, I'm assuming Mucinex is a significant contributor to Reckitt's over-the-counter portfolio. Can you share how Mucinex's performance compares to our other OTC brands and its importance to overall company revenue?

Why it matters: Establishes the strategic importance of Mucinex to Reckitt's business. Expected answer: Mucinex is a top performer, contributing X% to OTC revenue. Impact on approach: Higher contribution would lean towards a more conservative, market share-focused strategy.

• From a user perspective, I'm curious about customer loyalty within the cold and flu category. Do we have data on repeat purchase rates for Mucinex compared to competitors, and any insights on what drives brand switching?

Why it matters: Informs whether focus should be on retention or acquisition. Expected answer: Moderate loyalty with seasonal fluctuations. Impact on approach: Low loyalty might suggest need for product innovation, high loyalty could favor market share tactics.

• Regarding technical feasibility, I'm wondering about our R&D pipeline and manufacturing capabilities. How quickly could we bring new formulations to market, and are there any capacity constraints for scaling production of existing products?

Why it matters: Assesses our ability to execute on either strategy effectively. Expected answer: 12-18 months for new products, some flexibility in current production. Impact on approach: Long lead times might favor market share strategy, while excess capacity could support expansion.

• Looking at resource allocation, I'm thinking about the marketing and sales investments required for each option. Can you provide an overview of our current budget allocation between product development and market penetration initiatives?

Why it matters: Helps understand the financial implications of shifting focus. Expected answer: 70% market penetration, 30% product development. Impact on approach: Significant reallocation might be needed for expansion strategy, impacting short-term performance.